RXi Pharmaceuticals, The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc., University of Texas M.D. Anderson Cancer Center deal

The university and its not-for-profit partner granted RXi exclusive, worldwide rights to a cancer vaccine that targets folate binding protein-E39 (FBP). RXi plans to start Phase I trials by year end in ovarian/endometrial and breast cancers. The university and the foundation are eligible for upfront and milestone payments, plus single-digit royalties. The FBP vaccine consists of the E39 peptide combined with the immune adjuvant, granulocyte macrophage colony-stimulating factor (GM-CSF). Details were not disclosed. ...